Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 208, Issue 10, Pages 1553-1560Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jit460
Keywords
Acinetobacter; lwoffii; baumannii; MIC; antisense; PPMO; mouse; infection; respiratory infection; phosphorodiamidate morpholino oligomer
Categories
Funding
- Sarepta Therapeutics, Inc.
- N. L. Tartar fund
- National Institutes of Health [AI098724]
- University of Texas Southwestern Medical Center
Ask authors/readers for more resources
Background. Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) are synthetic DNA/RNA analogues that silence expression of specific genes. We studied whether PPMOs targeted to essential genes in Acinetobacter lwoffii and Acinetobacter baumannii are active in vitro and in vivo. Methods. PPMOs were evaluated in vitro using minimum inhibitory concentration (MIC) and viability assays, and in vivo using murine pulmonary infection models with intranasal PPMO treatment. Results. MICs of PPMOs ranged from 0.1 to 64 mu M (approximately 0.6-38 mu g/mL). The most effective PPMO tested was (RXR)(4)-AcpP, which is targeted to acpP. (RXR)(4)-AcpP reduced viability of A. lwoffii and A. baumannii by > 10(3) colony-forming units/mL at 5-8 times MIC. Mice treated with >= 0.25 mg/kg of (RXR)(4)-AcpP survived longer and had less inflammation and bacterial lung burden than mice treated with a scrambled-sequence PPMO or phosphate-buffered saline. Treatment could be delayed after infection and still increase survival. Conclusions. PPMOs targeted to essential genes of A. lwoffii and A. baumannii were bactericidal and had MICs in a clinically relevant range. (RXR)(4)-AcpP increased survival of mice infected with A. lwoffii or A. baumannii, even when initial treatment was delayed after infection. PPMOs could be a viable therapeutic approach in dealing with multidrug-resistant Acinetobacter species.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available